1. Home
  2. ILLR vs SVRA Comparison

ILLR vs SVRA Comparison

Compare ILLR & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ILLR
  • SVRA
  • Stock Information
  • Founded
  • ILLR 2015
  • SVRA N/A
  • Country
  • ILLR United States
  • SVRA United States
  • Employees
  • ILLR N/A
  • SVRA N/A
  • Industry
  • ILLR Investment Managers
  • SVRA Biotechnology: Pharmaceutical Preparations
  • Sector
  • ILLR Finance
  • SVRA Health Care
  • Exchange
  • ILLR Nasdaq
  • SVRA Nasdaq
  • Market Cap
  • ILLR 644.2M
  • SVRA 739.1M
  • IPO Year
  • ILLR N/A
  • SVRA N/A
  • Fundamental
  • Price
  • ILLR $3.81
  • SVRA $3.24
  • Analyst Decision
  • ILLR
  • SVRA Buy
  • Analyst Count
  • ILLR 0
  • SVRA 6
  • Target Price
  • ILLR N/A
  • SVRA $10.83
  • AVG Volume (30 Days)
  • ILLR 999.2K
  • SVRA 2.0M
  • Earning Date
  • ILLR 11-14-2024
  • SVRA 11-12-2024
  • Dividend Yield
  • ILLR N/A
  • SVRA N/A
  • EPS Growth
  • ILLR N/A
  • SVRA N/A
  • EPS
  • ILLR N/A
  • SVRA N/A
  • Revenue
  • ILLR $46,338,000.00
  • SVRA N/A
  • Revenue This Year
  • ILLR N/A
  • SVRA N/A
  • Revenue Next Year
  • ILLR N/A
  • SVRA N/A
  • P/E Ratio
  • ILLR N/A
  • SVRA N/A
  • Revenue Growth
  • ILLR N/A
  • SVRA N/A
  • 52 Week Low
  • ILLR $0.66
  • SVRA $2.82
  • 52 Week High
  • ILLR $8.86
  • SVRA $5.70
  • Technical
  • Relative Strength Index (RSI)
  • ILLR N/A
  • SVRA 40.37
  • Support Level
  • ILLR N/A
  • SVRA $2.82
  • Resistance Level
  • ILLR N/A
  • SVRA $4.30
  • Average True Range (ATR)
  • ILLR 0.00
  • SVRA 0.29
  • MACD
  • ILLR 0.00
  • SVRA -0.05
  • Stochastic Oscillator
  • ILLR 0.00
  • SVRA 25.76

About ILLR Triller Group Inc. Common Stock

Triller Group Inc is a us-based company that operates its businesses through Triller Corp which operates as a technology platform and AGBA Group Holding Limited operates as an insurance and wealth distribution platform.

About SVRA Savara Inc.

Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Share on Social Networks: